Drugs / RESCAP®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT03050476 | Nov 2017 → Sep 2025 | autoinflammatory syndrome | Alloksys Life Sciences B.V. | Unknown | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-08-02 | Alloksys Life Sciences B.V. | Results Alloksys reports interim results of its clinical phase IIb trial with Alkaline Phosphatase therapy RESCAP® in critical care patients alloksys.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-01-23 | Alloksys Life Sciences B.V. | Alloksys announces first patients enrolled in the continuation of the APPIRED III clinical trial with RESCAP® in patients undergoing cardiothoracic surgery alloksys.com ↗ |
| 2023-08-02 | Alloksys Life Sciences B.V. | Alloksys reports interim results of its clinical phase IIb trial with Alkaline Phosphatase therapy RESCAP® in critical care patients alloksys.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RESCAP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03050476 ↗ |
| Route | Intravenous | “intravenous application before, during, and for 24 or 96 hours after heart surgery” NCT03050476 ↗ |